Results 41 to 50 of about 76,984 (297)
The antifungal activity of tacrolimus in combination with antifungal agents against different fungal species has been previously reported. Here we report the in vitro interactions between tacrolimus and amphotericin B, fluconazole, itraconazole, and ...
Thaís Felli Kubiça+6 more
doaj +1 more source
GLed, a reversible lanthanide‐based GSH sensor that enables real‐time, single‐cell measurement of Gamma–Glutamyl Cysteine Ligase (GCL) activity ‐whose role in human T cells remains unclear‐ is developed. GLed directly links GCL activity to T cell effector functions and reveals its modulation by immunosuppressive drugs, identifying GCL as a critical ...
Francisco Fueyo‐González+9 more
wiley +1 more source
Background: Acute kidney injury (AKI) is common after lung transplant and may increase risk of chronic kidney disease (CKD). Calcineurin inhibitors (CNIs) such as tacrolimus contribute to AKI risk.
Carrie Burt+8 more
doaj +1 more source
Analysis of the histology of the scar bladder and biochemical parameters of rats with a solitary kidney undergoing immunosuppression with tacrolimus [PDF]
PURPOSE:To evaluate bladder histology in healing and biochemical analysis of rats with single kidney in ischemia/reperfusion, treated with tacrolimus.METHODS: Fifty rats randomized into five groups.
Ricardo Cavalheiro Cavalli+5 more
doaj +1 more source
ABSTRACTHereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies.
Hanny Al‐Samkari+22 more
wiley +1 more source
Abstract End‐ischemic viability testing by normothermic machine perfusion (NMP) represents an effective strategy to recover liver grafts having initially been discarded for liver transplantation (LT). However, its results in the setting of significant (≥30%) macrovesicular steatosis (MaS) have not been specifically assessed.
Damiano Patrono+8 more
wiley +1 more source
Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochrome ...
Eunjin Hong+6 more
doaj +1 more source
An interaction between tacrolimus and pristinamycin resulting in an elevated tacrolimus level [PDF]
We report a case of interaction between tacrolimus and pristinamycin. A 62-year-old man, Mr TM, presented with a 2-day history of increased pain and left knee swelling after a twisting injury. This occurred 1 year after renal transplantation for end-stage kidney disease from membranous glomerulonephropathy, complicated by an episode of acute rejection ...
Tehan, JV, Tan, SJ, Gregg, W, Dwyer, K
openaire +4 more sources
Long‐term immunosuppression of rabbits through oral tacrolimus administration
Oral gavage of rabbits with 1.5 mg/kg/d of tacrolimus allows for an efficient long‐term (1 year) immunosuppression with minimal side effects and no loss of animals. lmmunosuppressed rabbits are a convenient animal model to investigate the long‐term efficacy of human allografts in vivo.
Alexane Thibodeau+4 more
wiley +1 more source
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider+5 more
doaj +1 more source